Experimental drug for advanced solid tumors that have stopped responding to treatment
Part of Cancer clinical trials.
This study tests a new experimental drug called BR113, given as an injection, for people with advanced solid tumor cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have an advanced or metastatic solid tumor cancer that is not responding to standard treatments or has no standard treatment available.
- You need to have at least one tumor that can be measured on scans (e.g., CT or MRI).
- Your overall health should be good (able to do most daily activities) and your heart function must be within a normal range.
- You must be willing to provide a sample of your tumor tissue (from a previous biopsy or a new one).
- If you've had side effects from past cancer treatments, they must have mostly resolved before starting this trial.
- You cannot have previously received certain types of cancer drugs (like Trop-2 targeted therapies or exatecan-based drugs), and you must not have unstable fluid buildup in the chest or belly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
This study tests an experimental drug called SKB118 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
This trial tests a new drug called FL115, given as a shot under the skin, for people with advanced solid tumors that have stopped responding to standard treatments, including checkpoint inhibitors. The goal is to see if it can help shrink or control the tumors.
This trial tests an injection called MHB118C for people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The goal is to see if this new drug can help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.